DARA DARA Biosciences, Inc. featured news, full reports, and detailed charts
DARA Biosciences, Inc. (DARA) Wrap Up:
We use the term “Point” to describe our business prior to the merger transaction between Point Therapeutics, Inc. (“Point”) and DARA BioSciences, Inc. (“DARA”) completed on February 12, 2008. From May 1997 to May 2007, Point developed a family of dipeptidyl peptidase inhibitors for oncology and type 2 diabetes. Point studied its lead product candidate, talabostat, in a number of human clinical trials as a potential therapy in late-stage cancers. In May 2007, interim clinical results caused Point’s Independent Data Monitoring Committee to recommend stopping Point’s most advanced clinical trials, its two Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer. Subsequently, the talabostat clinical development program was put on clinical hold by the FDA. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f31%2f0001193125-08-070660.html#FIS_BUSINESS"www.darabiosciences.com
5 Employees
DARA BioSciences, Inc (DARA*(D):NASDAQ)
LAST $0.48 USD
CHANGE TODAY +0.045 10.47%
VOLUME 499.2K
*(D) = Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
As of 3:58 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of DARA BioSciences, Inc (DARA)
|
OPEN
$0.43
|
PREVIOUS CLOSE
$0.43
|
|
|
DAY HIGH
$0.48
|
DAY LOW
$0.43
|
|
|
52 WEEK HIGH
05/12/09 - $1.00
|
52 WEEK LOW
02/23/09 - $0.15
|
|
|
MARKET CAP
21.2M
|
AVERAGE VOLUME 3 mo
556.6K
|
|
|
DILUTED EPS TTM
$-0.16
|
SHARES OUTSTANDING
44.6M
|
|
|
DARA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
DARA Top Compensated Officers
Dr. Richard A. Franco Sr., R.Ph.
Chairman, Chief Executive Officer and Preside...
Age: 66
Total Annual Compensation: $133.3K
Dr. John Didsbury Ph.D.
Consultant
Age: 53
Total Annual Compensation: $294.4K
Mr. John C. Thomas Jr.
Consultant
Age: 55
Total Annual Compensation: $134.5K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for DARA BioSciences, Inc (DARA)
DARA Regains Compliance With NASDAQ Stockholders Equity Requirement
10/22/2009
DARA BioSciences, Inc on October 22, 2009 announced that it has received notification from The NASDAQ Stock Market indicating that the Company has demonstrated compliance with the $2.5 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b). As a result, the Company's securities will continue to trade on The NASDAQ Capital Market. As disclosed on September 17, 2009, the Company remains subject to a 180-day grace period, through March 15, 2010, to evidence compliance with NASDAQ's minimum bid price requirement. In the event the Company does not regain compliance by March 15, 2010, the Company may be eligible for an additional 180-day grace period if it meets the initial listing standards, with the exception of bid price, for The NASDAQ Capital Market.
DARA Biosciences Inc. Enters into Addendum and First Amendment to Material Transfer Agreement with America Stem Cell, Inc
10/12/2009
DARA BioSciences Inc. announced that the company has entered into an addendum and first amendment to Material Transfer Agreement with America Stem Cell Inc., pursuant to which the Material Transfer Agreement between the Company and ASC dated March 24, 2008 was amended. Under the Material Transfer Agreement, the company is providing ASC with dipeptidylpeptidase inhibitors from its proprietary library which ASC is using to further its research and development program related to hematopoietic stem cell transplants. Under the Material Transfer Agreement as amended, ASC is required to pay the Company a total of $250,000, in four equal installments over approximately three years, contingent upon ASC's receipt of a specified amount of grant funding for its HSC research and development program.
DARA BioSciences Gets Notice From NASDAQ
09/17/2009
On September 15, 2009, DARA BioSciences, Inc. received a notice from The NASDAQ Stock Market stating that the minimum bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with Marketplace Rule 5550(a)(2). The notification letter has no effect at this time on the listing of the Company's common stock on The NASDAQ Capital Market. DARA's common stock will continue to trade on The NASDAQ Capital Market under the symbol DARA. The notification letter states that DARA will be afforded 180 calendar days, or until March 15, 2010, to regain compliance with the minimum closing bid requirement. In accordance with Marketplace Rule 5810(c)(3)(a), the Company can regain compliance if the closing bid price of the Company's common stock meets or exceeds $1.00 per share for at least 10 consecutive business days. If the Company does not regain compliance by March 15, 2010, NASDAQ will provide written notification to the Company that the Company's securities are subject to delisting. In the event the Company does not regain compliance by March 15, 2010, the Company may be eligible for an additional 180 calendar day grace period if it meets the initial listing standards, with the exception of bid price, for The NASDAQ Capital Market.
DARA Competitors
| Company | Last | Change | |
| No competitor information is available for DARA. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | DARA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
DARA |
||
|
DARA transactions
| Type Date |
Target |
|
Private Placement
October 13, 2009 |
-- |
|
Private Placement
September 17, 2009 |
-- |
|
Private Placement
September 10, 2009 |
-- |
More Recent News About DARA Biosciences, Inc.
More news for DARA
DARA BioSciences Signs Definitive Agreement to Raise Approximately $750,000 in Registered Direct Offering
RALEIGH, N.C., Oct. 13, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA - News), a development-stage biopharmaceutical company, today announced that it has entered into a definitive agreement with institutional investors to sell 1,400,037 units, with each unit consisting of one share of the Company's common stock and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $750,000, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investors have agreed to purchase the units at a purchase price of $0.5357 per unit. The warrants, which represent the right to acquire 700,019 common shares, will be immediately exercisable and remain exercisable until the 5-year anniversary of the closing of the transaction at an exercise price of $0.4732 per share, which was the closing bid price of the Company's common shares on the NASDAQ Capital Market on October 12, 2009. Moody Capital Solutions, Inc. acted as placement agent for the offering. The transaction is expected to close on or about October 14, 2009, subject to satisfaction of customary closing conditions. The securities described above are being offered by DARA BioSciences, Inc. pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdict...Click here to read the whole Article (external link)
DARA BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib
Show all filings for DARA BIOSCIENCES, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for DARA BIOSCIENCES, INC. 13-Oct-2009Entry into a Material Definitive Agreement, Financial Statements and Exhib Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information p...Click here to read the whole Article (external link)
CEO Interview: ADVENTRX Pharmaceuticals, Inc. - Brian M. Culley
67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology Companies include: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cel...Click here to read the whole Article (external link)
DARA BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem
Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2009, DARA BioSciences, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors in connection with a registered direct offering by the Company (the "Offering") of 1,400,037 shares of the Company's common stock and 700,018 warrants to purchase shares of common stock (and the shares of common stock issuable from time to time upon exercise of the warrants). In the Offering, the common stock and warrants (the "Warrants") will be sold in units for $0.5357 per unit, with each unit consisting of one share of common stock and one-half of a warrant to purchase one share of common stock for each unit purchased. Under the Purchase Agreement, the units were sold at a closing that was completed on October 14, 2009 for gross proceeds of $750,000. Each Warrant will entitle the holder to purchase shares of common stock for an exercise price per share equal to $0.4732, which was the closing bid price of the Company's common shares on the NASDAQ Capital Market on October 12, 2009. The Warrants are immediately exercisable and expire October 14, 2014. A copy of the Purchase Agreement is attached hereto as Exhibit 10 and is incorporated herein by reference. A copy of the form of Warrant is attached hereto as Exhibit 4 and is incorporated herein by reference. Moody Capital Solutions, Inc. (the "Placement Agent") acted as the Company's placement agent for the Offering. The Placement Agent did not purchase or sell any units, nor is it required to arrange the purchase or sale of any minimum number or dollar amount of units. The Placement Agent agreed to use its best efforts to arrange for the sale of all of the units being offered in the Offering. The Placement Agent will be paid a cash fee equal to eight percent of the aggregate gross proceeds from the Offering. The shares of common stock and Warrants in ...Click here to read the whole Article (external link)
DARA BioSciences Regains NASDAQ Compliance
RALEIGH, N.C., Oct. 22, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA - News), a development-stage biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market indicating that the Company has demonstrated compliance with the $2.5 million stockholders' equity requirement set forth in NASDAQ Listing Rule 5550(b). As a result, the Company's securities will continue to trade on The NASDAQ Capital Market. As disclosed on September 17, 2009, the Company remains subject to a 180-day "grace" period, through March 15, 2010, to evidence compliance with NASDAQ's minimum bid price requirement. In the event the Company does not regain compliance by March 15, 2010, the Company may be eligible for an additional 180-day grace period if it meets the initial listing standards, with the exception of bid price, for The NASDAQ Capital Market. About DARA BioSciences, Inc. DARA BioSciences, Inc. is a Raleigh, North Carolina-based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the U.S. FDA. One of these drug candidates, KRN5500, has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, t...Click here to read the whole Article (external link)
CEO Interview: DARA BioSciences, Inc. - Dr. Richard Franco
67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology Companies include: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cel...Click here to read the whole Article (external link)
DARA BioSciences Secures Additional Intellectual Property Relating to Spicamycin (Including KRN5500)
RALEIGH, N.C., Nov. 4, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA - News) today announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 12/112,213 entitled "Methods for Decreasing or Preventing Pain Using Spicamycin Derivatives." When issued, the patent will allow protection through 2021. DARA BioSciences has exclusive licenses with Massachusetts General Hospital and Kirin Pharmaceuticals of Japan for the treatment of pain with Spicamycin derivatives. DARA currently has a patent estate with ownership, rights and licenses to 71 patents and 58 patent applications worldwide, covering the drug candidates in development plus its extensive libraries. Earlier this year, DARA successfully completed a clinical proof-of-concept study for the treatment of neuropathic pain in patients with advanced cancer using KRN5500. This 14 week, multi-center, double-blind, placebo-controlled dose escalation study randomized patients to receive treatment with either KRN5500 or placebo (saline equivalent) in doses ranging from 0.6 to 2.2 mg/m(2). The Primary Endpoint was achieved with demonstrating statistical significance over Placebo (p=0.03) in the median reduction of pain scores from baseline. The results of this Phase 2 study will be presented as a poster, "KRN5500 Demonstrates Significant Reduction in Neuropathic Pain Intensity in Patients with Cancer" at the 12th International Conference on the Mechanisms and Treatment o...Click here to read the whole Article (external link)
DARA BioSciences to Present at the 13th Annual Biotech & Specialty Pharmaceuticals Industry Investor Conference of the New York Society of Security Analysts ("NYSSA")
RALEIGH, N.C.--(BUSINESS WIRE)--DARA BioSciences, Inc. (NASDAQ: DARA)th Annual Biotech & Specialty Pharmaceuticals Industry investor conference to be held on December 1 in New York City. The New York Society of Security Analysts (NYSSA) serves 11,000 members and 30,000 Wall Street decision makers. “It is an honour for DARA to be invited to speak,†commented Richard Franco, DARA’s President, CEO and Chairman. â€DARA has two drug candidates in the clinic and this is a great opportunity to update the investment community on their progress.â€DARA is scheduled to present at 1:30pm EST on December 1. Interested parties can access a live web cast of the presentation through the Company’s website at www.darabio.com. A replay of the presentation will be available at the same location.About DARA BioSciences, Inc.DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a...Click here to read the whole Article (external link)
DARA BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report includes forward-looking statements based on our current management's expectations. There can be no assurance that actual results, outcomes or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, among others, our limited operating history, unpredictability of future program dispositions and operating results, competitive pressures and the other potential risks and uncertainties discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2008. Overview We are a Raleigh, North Carolina-based development stage biopharmaceutical company that acquires promising therapeutic drug candidates from third parties and advances their clinical development for later sale or license to healthcare companies. We operate a business model that focuses on the following: • Obtaining patents for innovative drug candidates which we believe have value in the marketplace; • Utilizing a small group of talented employees to develop those ideas through proof of concept in patients (generally through phase 2a clinical trials) by working with strategic outsource partners; and • Licensing the resulting product to a strong healthcare partner to commercialize. We do not intend to fully develop, obtain clearance from the U.S. Food and Drug Administration ("FDA") and then market the drug candidates we are developing. We hire experts with strong pharmaceutical project management s...Click here to read the whole Article (external link)
Would you like to leave a comment about DARA Biosciences, Inc. DARA
Find out what social network information about DARA Biosciences, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides DARA Biosciences, Inc. there is more great information available at Realpennies.com